Loading...

FITC anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_FITC_1_072111
Thioglycollate-elicited Balb/c macrophages were fixed/pemeabilized, and then stained with CD107b (Mac-3) APC and CD206 (clone C068C2) FITC (top) or rat IgG2a, κ FITC isotype control (bottom).
  • C068C2_FITC_1_072111
    Thioglycollate-elicited Balb/c macrophages were fixed/pemeabilized, and then stained with CD107b (Mac-3) APC and CD206 (clone C068C2) FITC (top) or rat IgG2a, κ FITC isotype control (bottom).
  • C068C2_FITC_2_072111
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
141703 50 µg 109€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
141704 200 µg 259€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  2. An S, et al. 2022. Int J Mol Sci. 23:. PubMed
  3. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  4. Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed
  5. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  6. Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed
  7. Wang C, et al. 2023. Int J Oral Sci. 15:19. PubMed
  8. Yang Y, et al. 2023. Diagnostics (Basel). 13:. PubMed
  9. Yashchenko A, et al. 2023. Front Immunol. 14:1082078. PubMed
  10. Liang S, et al. 2019. Mol Med Rep. 19:3707. PubMed
  11. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  12. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  13. Yang Q, et al. 2022. Br J Pharmacol. 179:1661. PubMed
  14. Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed
  15. Luo XB, et al. 2022. Ann N Y Acad Sci. 1514:116. PubMed
  16. Pannunzio B, et al. 2022. Cells. 11: . PubMed
  17. Ding L, et al. 2023. Immunology. 168:49. PubMed
  18. Napier TS, et al. 2023. Biomedicines. 11: . PubMed
  19. Han J, et al. 2023. Front Microbiol. 13:1067725. PubMed
  20. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  21. Kraynak CA, et al. 2022. Int J Pharm. 618:121634. PubMed
  22. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  23. Miao L, et al. 2020. Theranostics. 0.7625. PubMed
  24. Meng W, et al. 2021. JCI Insight. 6:. PubMed
  25. Keane T, et al. 2012. Biomaterials. 33:1771. PubMed
  26. Choi B, et al. 2017. Eur J Pharmacol. 10.1016/j.ejphar.2017.07.022. PubMed
  27. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  28. Kesavan R, et al. 2021. Int J Mol Sci. 22:. PubMed
  29. Zakeri A, et al. 2021. J Extracell Vesicles. 10:e12131. PubMed
  30. Wu R, et al. 2019. J Cell Mol Med. 24:1684. PubMed
  31. Li C, et al. 2022. Theranostics. 12:4581. PubMed
  32. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  33. Zhang W, et al. 2021. Front Immunol. 12:688294. PubMed
  34. Wada I, et al. 2021. Invest Ophthalmol Vis Sci. 62:17. PubMed
  35. Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed
  36. Lee S, et al. 2015. PLoS One. 10: 0132329. PubMed
  37. Hindi S, et al. 2012. Mol Cell Biol. 32:4833. PubMed
  38. Li H, et al. 2019. J Immunol Res. 2018:4807145. PubMed
  39. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  40. Uroda T, et al. 2020. Nat Protoc. 15:2107. PubMed
  41. Li K, et al. 2022. J Immunother Cancer. 10:. PubMed
  42. Yang Y, et al. 2022. Regen Biomater. 9:rbac023. PubMed
  43. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  44. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  45. Shin JE, et al. 2021. Heliyon. 7:e08433. PubMed
  46. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  47. Amo-Aparicio J, et al. 2021. Theranostics. 11:9805. PubMed
  48. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  49. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  50. Nguyen TKT, et al. 2020. Am J Pathol. 286:190. PubMed
  51. Yin S, et al. 2016. Nat Commun. 7: 11311. PubMed
  52. Yin T, et al. 2016. Sci Rep. 18:19534. PubMed
  53. Zhang F, et al. 2017. Mol Immunol. 10.1016/j.molimm.2017.06.019. PubMed
  54. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  55. Lee SS, et al. 2022. Commun Biol. 5:654. PubMed
  56. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  57. Lu CS, et al. 2020. J Hematol Oncol. 0.584722222. PubMed
  58. Li N, et al. 2021. eLife. 10:00. PubMed
  59. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  60. Wang W, et al. 2018. Oncogenesis. 7:97. PubMed
  61. Xie Z, et al. 2018. J Am Heart Assoc. 7:e007442. PubMed
  62. Lin S, et al. 2022. Nat Commun. 13:3301. PubMed
  63. Sun L, et al. 2015. J Immunol. 194:4891. PubMed
  64. Kida Y, et al. 2013. J Am Soc Nephrol. 24:559. PubMed
  65. Wang T, et al. 2018. Front Physiol. 9:209. PubMed
  66. Ishii H, et al. 2012. Cell Death Dis. 9;3:e363. PubMed
  67. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  68. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  69. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  70. Genoula M, et al. 2018. Front Immunol. 9:459. PubMed
  71. Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:1841. PubMed
  72. Zhou T, et al. 2022. Sci Adv. 8:eabj9617. PubMed
  73. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  74. Yang Y, et al. 2020. Cancer Biol Ther. 522:21. PubMed
  75. Ano Y, et al. 2019. Nutrients. 1.959027778. PubMed
  76. Miki Y, et al. 2022. JCI Insight. 7:. PubMed
  77. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  78. Shibata T, et al. 2020. J Clin Invest. 130:3021. PubMed
  79. Li Y, et al. 2015. Sci Rep. 5: 18648. PubMed
  80. Laban H, et al. 2018. J Cell Biol. 217:1503. PubMed
  81. Makino A, et al. 2021. iScience. 24:103201. PubMed
  82. Wang S, et al. 2022. J Inflamm Res. 14:7107. PubMed
  83. Liu Y, et al. 2015. BioMed Res Int. 2015 563425. PubMed
  84. Shen L, et al. 2016. Sci Rep. 6:30347. PubMed
  85. Cuccarese M, et al. 2017. Nat Commun. 8:14293. PubMed
  86. Yuan Y, et al. 2020. Front Physiol. 0.967361111. PubMed
  87. Grayczyk JP et al. 2017. Cell host & microbe. 22(5):678-687 . PubMed
  88. Wang X, et al. 2021. Cell. 184:5357. PubMed
  89. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  90. Kaji T, et al. 2012. J Exp Med. 80:3642. PubMed
  91. Wang S, et al. 2020. J Cell Mol Med. 24:722. PubMed
  92. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  93. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  94. Zhang A, et al. 2021. Theranostics. 11:3839. PubMed
  95. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  96. Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed
  97. Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed
  98. Gu L, et al. 2017. FASEB J. 31:3072. PubMed
  99. Perrotta C, et al. 2018. Front Immunol. 9:1186. PubMed
  100. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  101. Medina-Buelvas DM, et al. 2021. Pathogens. 10:. PubMed
  102. Gao R, et al. 2021. J Clin Invest. 131:. PubMed
  103. Chen Y, et al. 2021. Cancer Cell. 39(4):548-565.e6. PubMed
  104. Xue YL, et al. 2020. J Cell Mol Med. 24:12341. PubMed
  105. Zhang J, et al. 2014. J Immunol. 193:5149. PubMed
  106. Kim YD, et al. 2020. J Cancer. 11:4059. PubMed
  107. Chen Z, et al. 2016. Innate Immunity. 22: 419 - 432. PubMed
  108. Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed
  109. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  110. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  111. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
  112. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  113. Xue Y, et al. 2020. Sci Rep. 10:22265. PubMed
  114. Kapralov AA, et al. 2020. Nat Chem Biol. 278:16. PubMed
  115. Li J, et al. 2021. eLife. 10:00. PubMed
  116. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  117. Yao Y, et al. 2016. Mol Ther. 10.1038/mt.2016.36. PubMed
RRID
AB_10900988 (BioLegend Cat. No. 141703)
AB_10901166 (BioLegend Cat. No. 141704)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD206
Specificity Alt (DOES NOT SHOW ON TDS):
CD206
App Abbreviation (DOES NOT SHOW ON TDS):
ICFC,FC
UniProt
View information about CD206 on UniProt.org

Related FAQs

Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Go To Top Version: 4    Revision Date: 04-04-2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account